New Cancer Therapy:
The recent research publication in the Proceedings of the National Academy of Sciences has presented the concept of predicting breast cancer treatment responses through the proposed whole-tumor cell culture (WTC) model.
Considering the variable patient-to-patient responses to antineoplastic compounds in breast cancer, Xinsong Chen proposed the model. Being a Ph.D., from Karolinska Institute in Stockholm, assessed the WTC ex vivo model for predicting drug response in breast cancer.
The researchers found that the model could be promising for all breast tumors with a high success rate (98 of 116). It can reassemble the parental tumors with the endogenous microenvironment.
Moreover, investigations on breast cancer therapies with WTCs provide strong clinical associations and predictive values. Furthermore, in a validation study with neoadjuvant treatment regimens, the correlation between WTC-based test results and patients’ clinical responses supported the accuracy of the model.
The WTC model allowed for personalised drug testing within 10 days even for small-sized tumors. Additionally, WTC testing can stratify patient groups for clinical trials associated with genomic and transcriptomic analyses.
The preclinical model can have a significant impact on academic research and pharmaceutical drug development.
Furthermore, read more latest news from today, Jan 5, 2023:
Clinical Trial Updates- Global
First treatment approval for advanced ASPS (EPR)
First patient enrolled in cisplatin-induced ototoxicity Phase II trial (EPR)
Pharmaceutical Marketing Updates- Global
Janssen submits marketing application for bispecific antibody (EPR)
Physician updates – Global
Biologic Age Up for Those With Serum Sodium >142 mmol/L (PW)
Adverse Events Increased for Induced Abortion With Mifepristone-Misoprostol (PW)
See and learn more about our website by clicking on the internal links below:
- Global Healthcare trends: WHO meets with Chinese officials on current COVID-19 situation
- Healthcare trends 2022: Immune Suppression Impacts Risk for Breakthrough Infection after COVID-19 Vaccination
- Healthcare trends 2022: India on alert for new variants as COVID wave sweeps China
- Healthcare trends 2022: China stares at another COVID-19 crisis; can India stay immune?
- Clinical Drug Development Process: First targeted delivery of siRNA into muscle
- Biologics development: First leukemia patient given base-edited CAR T cells
- Clinical Phases of Drug Development: Dostarlimab combination facilitates promising lung cancer survival
- Healthcare technology news: AI-enabled Imaging of Retina Can Specify Heart Disease Risk
- Latest radiotherapy news today: Radiotherapy with immunotherapy increases lung cancer survival-Hidoc Updates
- Pharma Global News: FDA approves first gene therapy for Hemophilia B–Hidoc Updates
- Healthcare News Today Features AI Tool Reduces Risk of COVID-19 – Hidoc Updates
- Government forms new regulation called the Uniform Code of Pharma Marketing Practices – Hidoc Updates
- A Rare Genetic Disorder Is Treated In The Womb – Hidoc Updates
- Simple ways to engage Doctors at Conferences? – Hidoc Updates
About Hidoc Dr:
Our company Hidoc Dr. is a Digital Platform for Doctors with an audited reach of 8 Lakh Doctors across India. Additionally, Hidoc Dr. provides Digital Marketing services to your brands to reach Doctors across all Specializations and Geographies. Furthermore, Hidoc Digital Solutions guarantee 3x Brand Recall compared to any other digital solutions today.
Leave a Reply